Archive for the ‘Lyme’ Category

SOT Treatment For Lyme Disease

SOT was created for those with previously untreatable genetic conditions.  In my opinion, Lyme disease is not a genetic condition, it’s an infection(s) and depending upon your exact case, is only one of many potential infections that can be bacterial, fungal, viral, and/or parasitic.  This is my main problem with SOT besides the fact it is a gene-silencing technique that raises questions about long-term effects as well as the fact Bb changes its outer surface protein, is stealthy, and very probably a bioweaponized pathogen(s) created in a lab to be more persistent and transmissible, and to evade the immune system and treatment.

https://www.treatlyme.net/guide/sot-lyme-treatment

SOT for Lyme Image from Marty Ross MD
 
By Marty Ross MD

Supportive Oligonucleotide Therapy (SOT) Background

Supportive Oligonucelotide Therapy (SOT) is a new treatment for Lyme disease. SOT is also called Antisense Oligonucelotide Therapy (ASOT) which is the term used in medical research papers. SOT uses laboratory derived nucleic acids (genetic code) that blocks production of disease causing proteins or even gene expression. These pieces of genetic code are called oligonucleotides. You can think of oligonucleotides as a genetic message.

For example, in Duchenne Muscular Dystrophy (DMD), SOT provides oligonucleotides that direct the correct production of a protein called dystrophin. People with muscular dystrophy are born with DNA that provides the wrong genetic message for dystrophin. SOT correction to the DNA message leads to production of dystrophin. This prevents the muscle damage seen in DMD.

In Lyme disease, a currently available type of SOT produced by RGCC in Greece uses oligonucleotides intended to stop germ growth and replication. Unlike the SOT therapy for Duchenne muscular dystrophy, the Lyme SOT is not a US Food and Drug Administration (FDA) approved drug. To be approved by the FDA, a therapy must have scientific evidence of safety and effectiveness.  (See link for article)

______________________

**Comment**

Dr. Ross is unsure if SOT for Lyme/MSIDS works, and some of his patients using it before seeing him experienced little to no effects, but some of his colleagues state some patients have experienced improvement.  He also reminds readers that there is a placebo effect of 35% on average in clinical trials for drugs.

Also, please read this article on SOT Therapy side effects.

Common side effects: injection site reactions, flu-like symptoms, headaches and fatigue, changes in liver function.

Serious but supposedly rare side effects: thrombocytopenia, changes in kidney function, allergic reactions, neurological effects, potential impact on fertility and pregnancy.

For more on SOT:

For more on the RGCC test:

 

 

 

 

Mom Dealing With PANS & Lyme: “2020 is NOT My Worst Year”

https://www.lymedisease.org/from-a-mom-dealing-with-pans-and-lyme-2020-is-not-my-worst-year/

From a mom dealing with PANS and Lyme: “2020 is NOT my worst year”

Symptomatic High-Grade AV Block & Phase 4 Right Bundle Branch Block – A Previously Unreported Manifestation in Lyme Carditis

https://www.heartrhythmcasereports.com/article/S2214-0271(20)30263-3/fulltext#secsectitle0020

Phase 4 Block of the Right Bundle Branch Suggesting His-Purkinje System Involvement in Lyme Carditis

Open AccessPublished: December 01, 2020DOI:https://doi.org/10.1016/j.hrcr.2020.11.017
We describe an adolescent with symptomatic high-grade AV block and evidence of phase 4 right bundle branch block, a previously unreported manifestation of infra-nodal conduction system involvement in LC.

A previously healthy 14-year-old boy presented via emergency medical services in mid-summer because of syncope (fainting).

Interesting findings:

  • Patient frequently hunts and fishes in wooded, Lyme-endemic region 
  • Didn’t remember tick bites or EM rash
  • Two weeks prior to ER visit patient had a runny nose, cough, abdominal pain, followed by headache and nausea.
  • In the ER he had bradycardia, altered mental status, headache, and vomiting.
  • Initial ECG showed complete heart block
  • He was given 2,000mg of IV Ceftriaxone every 24 hours
  • Testing supported clinical suspicion of Lyme
  • He was given a temporary pace-maker which was removed after 5 days of IV antibiotics and he was switched to oral doxycycline to complete a total of 21 days of antibiotics
  • After being monitored in hospital for 7 days, he was discharged with an auto-detecting wireless monitor until a follow-up appointment and stress test
  • Follow-up appointment patient was well with normal ECG

_____________________

**Comment*

Case study states: 

Significant AV block due to LC occurs in about 1% of LD cases.

I believe this statistic is premature considering many do not test positive and therefore are undiagnosed. I’ve posted numerous articles where patients are sent packing even when they present with positive test results three times in a row! We will never know how many patients with AV block have an underlying tick-borne illness due to abysmal testing and the lack of training and experience of most doctors with tick-borne illness.

And then there’s that nagging concern about long-term effects and if 21 days of antibiotics were enough for his patient. It often isn’t.

Please see:

https://madisonarealymesupportgroup.com/2020/11/25/what-makes-a-doctor-lyme-literate/

Risk of Development of Chronic Kidney Disease After Exposure to Borrelia Burgdorferi and Anaplasma spp

https://pubmed.ncbi.nlm.nih.gov/33152525/

Risk of Development of Chronic Kidney Disease After Exposure to Borrelia burgdorferi and Anaplasma spp

PMID: 33152525

DOI: 10.1016/j.tcam.2020.100491

Free article

Abstract

Lyme disease is a multi-faceted illness caused by infection due to Borrelia burgdorferi. Acute kidney damage secondary to Lyme disease is well described but less so as a chronic event. The role of Anaplasma spp. and secondary kidney dysfunction is not known. A retrospective cohort study was performed to determine if dogs within a defined Lyme disease and anaplasmosis region with B. burgdorferi or Anaplasma spp. antibodies had an increased risk of chronic kidney disease (CKD). Patient exposure was defined as having a B. burgdorferi or Anaplasma spp. antibody positive result recorded at any point in the available patient history. CKD was defined as concurrent increased symmetric dimethylarginine and creatinine (Cr) for a minimum of 25 days with inappropriate urine specific gravity (USG). Patients were matched using propensity scoring to control for age, region, and breed. Contingency tables were used to compare dogs seropositive and not seropositive to B. burgdorferi and Anaplasma spp. and CKD outcome. For each comparison that was performed, statistical significance was defined by a P-value of <.025. The risk ratio of CKD for patients exposed to B. burgdorferi and Anaplasma spp. were found to be 1.43 (95% confidence interval [CI, 1.27, 1.61], P < .0001) and 1.04, (95% CI [0.87, 1.24], P = .6485), respectively.

Results suggest in this cohort no increased risk for developing CKD when exposed to Anaplasma spp. but a significant increase in risk for developing CKD with exposure to B. burgdorferi.

_____________________

For more:  https://madisonarealymesupportgroup.com/2019/03/08/lyme-nephritis-in-humans-physio-pathological-bases-spectrum-of-kidney-lesions/

https://madisonarealymesupportgroup.com/2020/12/15/lyme-disease-is-a-small-vessel-disease-dr-klemann/

Interactions Between Borrelia Burgdorferi & Ticks

https://pubmed.ncbi.nlm.nih.gov/32651470/

Interactions between Borrelia burgdorferi and ticks

    Free PMC article

    Abstract

    Borrelia burgdorferi is the causative agent of Lyme disease and is transmitted to vertebrate hosts by Ixodes spp. ticks. The spirochaete relies heavily on its arthropod host for basic metabolic functions and has developed complex interactions with ticks to successfully colonize, persist and, at the optimal time, exit the tick. For example, proteins shield spirochaetes from immune factors in the bloodmeal and facilitate the transition between vertebrate and arthropod environments. On infection, B. burgdorferi induces selected tick proteins that modulate the vector gut microbiota towards an environment that favours colonization by the spirochaete. Additionally, the recent sequencing of the Ixodes scapularis genome and characterization of tick immune defence pathways, such as the JAK-STAT, immune deficiency and cross-species interferon-γ pathways, have advanced our understanding of factors that are important for B. burgdorferi persistence in the tick. In this Review, we summarize interactions between B. burgdorferi and I. scapularis during infection, as well as interactions with tick gut and salivary gland proteins important for establishing infection and transmission to the vertebrate host.